Eli Lilly Retatrutide Boom: Triple-Agonist Trial Shock
Can Eli Lilly Retatrutide’s powerful Phase 3 diabetes data reignite confidence in the GLP-1 boom despite rising competitive and pricing fears? Maik Kemper Editor in…
Eli Lilly Forecast Warning after HSBC’s bearish reset
Is the latest bearish Eli Lilly Forecast a rare buying opportunity or the start of a painful valuation reset in GLP-1 leaders? Maik Kemper Editor…
Eli Lilly Investment -$37.70: Rally Warning for Bulls
Can the latest Eli Lilly Investment wave in GLP-1 plants and AI supercomputing still justify a trillion-dollar style valuation? How does the Eli Lilly Investment…